Legend Biotech (LEGN) Projected to Post Earnings on Tuesday

Legend Biotech (NASDAQ:LEGN) will likely be posting its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect Legend Biotech to post earnings of ($0.34) per share and revenue of $179.00 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Legend Biotech Stock Up 3.2 %

Legend Biotech stock opened at $35.26 on Friday. The stock has a market capitalization of $6.44 billion, a PE ratio of -37.12 and a beta of 0.19. Legend Biotech has a 12 month low of $30.17 and a 12 month high of $69.24. The business has a 50 day simple moving average of $35.36 and a 200-day simple moving average of $41.55. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.98 and a quick ratio of 4.90.

Analyst Ratings Changes

A number of research firms have recently commented on LEGN. Cantor Fitzgerald restated an “overweight” rating and issued a $83.00 price objective on shares of Legend Biotech in a research report on Monday, December 9th. Royal Bank of Canada restated an “outperform” rating and issued a $86.00 price objective on shares of Legend Biotech in a research report on Monday, December 9th. Piper Sandler restated an “overweight” rating and issued a $78.00 price objective on shares of Legend Biotech in a research report on Monday, December 30th. Finally, HC Wainwright restated a “buy” rating and issued a $73.00 price objective on shares of Legend Biotech in a research report on Tuesday, January 21st. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Legend Biotech has an average rating of “Buy” and an average price target of $79.50.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).